CNBG-Virogin Biotech (Shanghai) Ltd.
- Trials
- 0
- Subs
- 0
- People
- 0
- Links
- 0
Executive Summary
AI synthesisCNBG-Virogin Biotech is a Shanghai-based biotech entity with limited public information available, making due diligence challenging. The company appears to have CNBG (China National Biotec Group) involvement based on naming, which could indicate state-owned enterprise connections. With no disclosed pipeline, key personnel, or recent deal activity, this entity presents high information opacity risks typical of early-stage Chinese biotechs. BIOSECURE risk appears low based on current designation status.
Structure: Corporate structure is unclear due to lack of disclosed information about parent entities, subsidiaries, or ownership arrangements. The CNBG naming suggests potential ties to China National Biotec Group, a major state-owned pharmaceutical conglomerate, but this relationship is not confirmed. Standard VIE structure analysis would be required during due diligence given the Chinese domicile.
BIOSECURE Risk
Currently shows 'clear' BIOSECURE status with no BCC designation, indicating no current regulatory restrictions
Key Exposures:
- •Potential undisclosed CNBG/state-owned enterprise connections
- •Shanghai location in key biotech hub
- •Limited transparency on ownership structure
Mitigation: No public information available on BIOSECURE compliance measures or mitigation strategies
BD Intelligence
Therapeutic Areas:
Recent Deals: No recent deal activity identified
Approach: Exercise extreme caution - conduct thorough due diligence on corporate structure, ownership, and actual business operations before any engagement
Red Flags
- ⚠Complete lack of public information on pipeline, management, and operations
- ⚠Unclear relationship to CNBG despite naming convention
- ⚠No disclosed key personnel or corporate governance
- ⚠Absence of recent corporate events or deal activity
- ⚠Potential information opacity issues typical of shell entities
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 0
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.